MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317525 | Name: Cidofovir
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cidofovir is a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor that is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis in people with AIDS. The mechanism of action of cidofovir is as a DNA Polymerase Inhibitor. The chemical classification of cidofovir anhydrous is Nucleoside Analog.

Chemical Structure

Cidofovir
Cidofovir
CAS#113852-37-2 (free base)

Theoretical Analysis

MedKoo Cat#: 317525

Name: Cidofovir

CAS#: 113852-37-2 (free base)

Chemical Formula: C8H14N3O6P

Exact Mass: 0.0000

Molecular Weight: 279.19

Elemental Analysis: C, 34.42; H, 5.05; N, 15.05; O, 34.38; P, 11.09

Price and Availability

Size Price Availability Quantity
50mg USD 350.00 2 Weeks
100mg USD 550.00 2 Weeks
250mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
149394-66-1 (hydrate) 127749-27-3 (sodium) 113852-37-2 (free base)
Synonym
Cidofovir; Vistide; HPMPC; (S)-HPMPC; Cidofovir anhydrous; GS-504; GS 504; GS504; GS-0504; GS 0504; GS0504;
IUPAC/Chemical Name
(S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid
InChi Key
VWFCHDSQECPREK-LURJTMIESA-N
InChi Code
InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
SMILES Code
OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 279.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P; CIDAN127412 GESIDA Study Group. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. AIDS. 2016 Jan 2;30(1):75-82. doi: 10.1097/QAD.0000000000000886. PubMed PMID: 26731755. 2: Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, Labussiere-Wallet H, Thomas X, Nicolini FE, Wattel E, Ducastelle-Leprêtre S, Barraco F, Lebras L, Salles G, Michallet M, Rioufol C. Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation: a retrospective study and a literature review. Biol Blood Marrow Transplant. 2015 Dec 21. pii: S1083-8791(15)01876-5. doi: 10.1016/j.bbmt.2015.12.009. [Epub ahead of print] PubMed PMID: 26718666. 3: Santesteban R, Feito M, Mayor A, Beato M, Ramos E, de Lucas R. Trichodysplasia Spinulosa in a 20-Month-Old Girl With a Good Response to Topical Cidofovir 1. Pediatrics. 2015 Dec;136(6):e1646-9. doi: 10.1542/peds.2015-0953. PubMed PMID: 26620059. 4: Ledbetter EC, Spertus CB, Pennington MR, Van de Walle GR, Judd BE, Mohammed HO. In Vitro and In Vivo Evaluation of Cidofovir as a Topical Ophthalmic Antiviral for Ocular Canine Herpesvirus-1 Infections in Dogs. J Ocul Pharmacol Ther. 2015 Dec;31(10):642-9. doi: 10.1089/jop.2015.0024. Epub 2015 Sep 29. PubMed PMID: 26418618. 5: Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2015 Nov 26. pii: dkv393. [Epub ahead of print] PubMed PMID: 26612873. 6: Pozzuto T, Röger C, Kurreck J, Fechner H. Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir. Antiviral Res. 2015 Aug;120:72-8. doi: 10.1016/j.antiviral.2015.05.010. Epub 2015 May 27. PubMed PMID: 26026665. 7: Moore E, Kovarik C. Intralesional cidofovir for the treatment of a plantar wart. J Am Acad Dermatol. 2015 Jul;73(1):e23-4. doi: 10.1016/j.jaad.2015.02.1143. PubMed PMID: 26089066. 8: Caruso Brown AE, Cohen MN, Tong S, Braverman RS, Rooney JF, Giller R, Levin MJ. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2015 Jul;59(7):3718-25. doi: 10.1128/AAC.04348-14. Epub 2015 Mar 2. PubMed PMID: 25733509; PubMed Central PMCID: PMC4468698. 9: San Giorgi MR, Tjon Pian Gi RE, Dikkers FG. The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors. Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1819-20. doi: 10.1007/s00405-014-3366-y. Epub 2014 Oct 29. PubMed PMID: 25351501. 10: Rascon J, Verkauskas G, Pasauliene R, Zubka V, Bilius V, Rageliene L. Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. Pediatr Transplant. 2015 Jun;19(4):E111-4. doi: 10.1111/petr.12477. Epub 2015 Apr 16. PubMed PMID: 25882393. 11: Jeffers-Francis LK, Burger-Calderon R, Webster-Cyriaque J. Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system. Antiviral Res. 2015 Jun;118:46-55. doi: 10.1016/j.antiviral.2015.02.002. Epub 2015 Mar 16. PubMed PMID: 25790744; PubMed Central PMCID: PMC4424161. 12: Padilla España L, Del Boz J, Fernández-Morano T, Escudero-Santos I, Arenas-Villafranca J, de Troya M. Recalcitrant warts and topical cidofovir: predictive factors of good response. J Eur Acad Dermatol Venereol. 2015 Apr 10. doi: 10.1111/jdv.13145. [Epub ahead of print] PubMed PMID: 25864554. 13: Lee SS, Ahn JS, Jung SH, Ahn SY, Kim JY, Jang HC, Kang SJ, Jang MO, Yang DH, Kim YK, Lee JJ, Kim HJ. Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. Korean J Intern Med. 2015 Mar;30(2):212-8. doi: 10.3904/kjim.2015.30.2.212. Epub 2015 Feb 27. PubMed PMID: 25750563; PubMed Central PMCID: PMC4351328. 14: Liekens S, Noppen S, Gijsbers S, Sienaert R, Ronca R, Tobia C, Presta M. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget. 2015 Mar 10;6(7):4633-48. PubMed PMID: 25609197; PubMed Central PMCID: PMC4467104. 15: Lugthart G, Oomen MA, Jol-van der Zijde CM, Ball LM, Bresters D, Kollen WJ, Smiers FJ, Vermont CL, Bredius RG, Schilham MW, van Tol MJ, Lankester AC. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant. 2015 Feb;21(2):293-9. doi: 10.1016/j.bbmt.2014.10.012. Epub 2014 Oct 16. PubMed PMID: 25464118. 16: Zhang X, Wang R, Piotrowski M, Zhang H, Leach KL. Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 2015 Feb;29(1):251-8. PubMed PMID: 25448811. 17: Andrei G, Topalis D, De Schutter T, Snoeck R. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia. Antiviral Res. 2015 Feb;114:21-46. doi: 10.1016/j.antiviral.2014.10.012. Epub 2014 Oct 30. Review. PubMed PMID: 25446403. 18: Tuğcu-Demiröz F, Acartürk F, Özkul A. Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery. J Biomater Sci Polym Ed. 2015;26(17):1237-55. doi: 10.1080/09205063.2015.1082808. Epub 2015 Sep 24. PubMed PMID: 26300445. 19: Kim SJ, Kim K, Park SB, Hong DJ, Jhun BW. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One. 2015 Apr 15;10(4):e0122642. doi: 10.1371/journal.pone.0122642. eCollection 2015. PubMed PMID: 25875735; PubMed Central PMCID: PMC4398328. 20: Ma F, Nan K, Lee S, Beadle JR, Hou H, Freeman WR, Hostetler KY, Cheng L. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system. Eur J Pharm Biopharm. 2015 Jan;89:271-9. doi: 10.1016/j.ejpb.2014.12.010. Epub 2014 Dec 13. PubMed PMID: 25513956; PubMed Central PMCID: PMC4355386.